These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30827232)

  • 1. Diabetes-induced Alterations in HDL Subfractions Distribution.
    Femlak M; Gluba-Brzozka A; Franczyk B; Rysz J
    Curr Pharm Des; 2020; 26(27):3341-3348. PubMed ID: 30827232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.
    Femlak M; Gluba-Brzózka A; Ciałkowska-Rysz A; Rysz J
    Lipids Health Dis; 2017 Oct; 16(1):207. PubMed ID: 29084567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome.
    Kidawa M; Gluba-Brzózka A; Zielinska M; Franczyk B; Banach M; Rysz J
    Curr Vasc Pharmacol; 2019; 17(4):365-375. PubMed ID: 29852873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy.
    Kanca D; Gormus U; Tokat B; Eronat AP; Bugra Z; Ozturk O; Yilmaz-Aydogan H
    Biochem Genet; 2017 Apr; 55(2):168-182. PubMed ID: 27900488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes.
    Zhao X; Zhang HW; Zhang Y; Li S; Xu RX; Sun J; Zhu CG; Wu NQ; Gao Y; Guo YL; Liu G; Dong Q; Li JJ
    Heart Lung Circ; 2017 Mar; 26(3):211-218. PubMed ID: 28027866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
    Gluba-Brzózka A; Franczyk B; Banach M; Rysz-Górzyńska M
    Int Urol Nephrol; 2017 Jan; 49(1):155-164. PubMed ID: 27942970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: An age- and gender-matched case-control study.
    Zhang W; Jin J; Zhang H; Zhu Y; Dong Q; Sun J; Guo Y; Dou K; Xu R; Li J
    Front Endocrinol (Lausanne); 2022; 13():1041555. PubMed ID: 36714594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia in type 2 diabetes mellitus.
    Gadi R; Samaha FF
    Curr Diab Rep; 2007 Jun; 7(3):228-34. PubMed ID: 17547840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment.
    Harangi M; Seres I; Harangi J; Paragh G
    Cardiovasc Drugs Ther; 2009 Dec; 23(6):501-10. PubMed ID: 19859794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein profile in newly-diagnosed lower extremity artery disease in Slovak population without diabetes mellitus.
    Kasko M; Gaspar L; Dukát A; Gavorník P; Oravec S
    Neuro Endocrinol Lett; 2014; 35(6):531-5. PubMed ID: 25433844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
    Muñoz-Hernandez L; Ortiz-Bautista RJ; Brito-Córdova G; Lozano-Arvizu F; Saucedo S; Pérez-Méndez O; Zentella-Dehesa A; Dauteuille C; Lhomme M; Lesnik P; Chapman MJ; Kontush A; Aguilar Salinas CA
    Atherosclerosis; 2018 Oct; 277():72-79. PubMed ID: 30176567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase 1 and HDL subfractions in hypercholesterolemic children and adolescents.
    Duracková Z; Muchová J; Andrezálová L; Oravec S; Nagyová Z; Garaiova I
    Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S29. PubMed ID: 26461330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dysfunctional high-density lipoproteins in diabetes mellitus].
    Poteryaeva ON; Usynin IF
    Probl Endokrinol (Mosk); 2022 Jun; 68(4):69-77. PubMed ID: 36104968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.